赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNY 赛诺菲安万特

已收盘 07-02 16:00:00 EDT

48.54

-1.05

-2.12%

盘后48.54

+0.000.00%

16:57 EDT

最高48.85	最低48.45	成交量265.39万
今开48.85	昨收49.59	日振幅0.81%
总市值1,214亿	流通市值1,067亿	总股本25.00亿
成交额1.29亿	换手率0.12%	流通股本21.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":48.54,"timestamp":1719950400000,"preClose":49.59,"halted":0,"volume":2653909,"hourTrading":{"tag":"盘后","latestPrice":48.54,"preClose":48.54,"latestTime":"16:57 EDT","volume":13939,"amount":676583.7,"timestamp":1719953839187},"delay":0,"floatShares":2198660363,"shares":2500233816,"eps":1.949656,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.05,"latestTime":"07-02 16:00:00 EDT","open":48.85,"high":48.85,"low":48.45,"amount":129247172.95811999,"amplitude":0.008066,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.949656,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1719993600000},"adr":1,"listingDate":1025496000000,"adjPreClose":49.59,"adrRate":0.5,"dividendRate":0.041524,"preHourTrading":{"tag":"盘前","latestPrice":48.84,"preClose":49.59,"latestTime":"09:29 EDT","volume":2115,"amount":103282.11225,"timestamp":1719926970080},"postHourTrading":{"tag":"盘后","latestPrice":48.54,"preClose":48.54,"latestTime":"16:57 EDT","volume":13939,"amount":676583.7,"timestamp":1719953839187},"volumeRatio":0.918728,"impliedVol":0.2928,"impliedVolPercentile":0.8492},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"2448926883","title":"隔夜美股全复盘(7.2)| 特斯拉涨逾6%，马斯克称XAI的GROK 2大模型将于八月推出","url":"https://stock-news.laohu8.com/highlight/detail?id=2448926883","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448926883?lang=zh_cn&edition=full","pubTime":"2024-07-02 06:09","pubTimestamp":1719871786,"startTime":"0","endTime":"0","summary":"特斯拉涨逾6%，马斯克称XAI的GROK 2大模型将于八月推出","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/822830","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BA","IE00B7KXQ091.USD","03165","IE00BLSP4452.SGD","JD","MRK","BK4564","LU1267930813.SGD","TSLL","CHWY","LU0211327993.USD","LU1914381329.SGD","IE00B19Z9505.USD","BK4097","LU0061474960.USD","LU0648001328.SGD","NIO","AMZN","BK4567","MSFT","IE00B19Z3B42.SGD","BK4514","IE0002270589.USD","BK4516","PDD","NVDA","EVS.SI","BK4511","ASML","GOOG","LU0082616367.USD","BK4200","LU0122379950.USD","SPR","XPEV","BK4533","09866","LU0234572021.USD","META","SNY","TSLA","03145","LU0316494557.USD","LU0053666078.USD","TSM","IE00BLSP4239.USD","LU1023059063.AUD","IE00BBT3K403.USD","LU1057294990.SGD","IE0009356076.USD","AAPL"],"gpt_icon":0},{"id":"2446532680","title":"赛诺菲安万特战略投资临床阶段生物技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2446532680","media":"企查查","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446532680?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:26","pubTimestamp":1719491218,"startTime":"0","endTime":"0","summary":"6月27日，临床阶段生物技术公司Vigil Neuroscience表示，赛诺菲安万特以每股7.44美元的折算价格对该公司进行了4000万美元的战略投资。消息发布后，Vigil Neuroscience盘前一度上涨58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062720270195de466d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062720270195de466d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4588","BK4585","SNY"],"gpt_icon":0},{"id":"2446814531","title":"获赛诺菲安万特(SNY.US)战略投资4000万美元，Vigil Neuroscience(VIGL.US)大涨近30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446814531","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446814531?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:16","pubTimestamp":1719490563,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物技术公司Vigil Neuroscience表示，赛诺菲安万特以每股7.44美元的折算价格对该公司进行了4000万美元的战略投资。消息发布后，Vigil Neuroscience盘前一度上涨了58.20%，截至发稿，盘前上涨了29.63%。据悉，赛诺菲将购买Vigil 537,634股A系列无投票权优先股，每股可转换为10股普通股。Vigil将利用所得资金支持其研发活动。赛诺菲将获得Vigil小分子TREM2激动剂项目许可的独家优先谈判权，包括目前正在进行一期临床研究的VG-3927。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VIGL","BK4139","SNY","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2441780264","title":"隔夜美股全复盘(6.6)| 3万亿市值俱乐部纳新！英伟达涨逾5%，超越苹果成全球市值第二","url":"https://stock-news.laohu8.com/highlight/detail?id=2441780264","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441780264?lang=zh_cn&edition=full","pubTime":"2024-06-06 07:47","pubTimestamp":1717631269,"startTime":"0","endTime":"0","summary":"3万亿市值俱乐部纳新！英伟达涨逾5%，超越苹果成全球市值第二","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/775451","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0444971666.USD","LU0861579265.USD","SG9999004220.SGD","LU1803068979.SGD","INTC","BK4571","BK4575","SNY","LU0198837287.USD","LU0689472784.USD","LU2326559502.SGD","BK4141","BK4576","IE00BJJMRY28.SGD","GOOG","LU1839511570.USD","LU1861558580.USD","LU0109392836.USD","BK4579","LU1668664300.SGD","03145","IE00BMPRXN33.USD","OXY","APO","AAPL","IE00BD6J9T35.USD","ASML","LU0289941410.SGD","LU0149725797.USD","LU0820561909.HKD","IE00B3M56506.USD","LU0289739343.SGD","NXPI","BK4077","LU0175139822.USD","LU0541501648.USD","LU1992135399.USD","BK4507","03165","LU2063271972.USD","LU2756315318.SGD","BK4503","LU0820561818.USD","LU1282649067.USD","NVDA","LU0289961442.SGD","WBD","BK4501","TSM","BA"],"gpt_icon":0},{"id":"2441658290","title":"预防婴幼儿RSV感染 赛诺菲(SNY.US)鼻喷疫苗在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2441658290","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441658290?lang=zh_cn&edition=full","pubTime":"2024-06-05 11:12","pubTimestamp":1717557148,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲近日宣布，其婴幼儿鼻喷呼吸道合胞病毒减毒活疫苗已经获得中国国家药监局药品审评中心批准开展临床研究。RSVt疫苗是一款被设计用于预防呼吸道合胞病毒引起疾病的婴幼儿疫苗，可为6至24月龄的婴幼儿提供保护。据悉，合胞病毒是引起婴幼儿急性上呼吸道感染常见的病毒病原。此前，RSVt疫苗在全球1/2期临床试验中获得积极结果。数据显示，两剂次RSVt疫苗具有与安慰剂相似的耐受性，并能够诱导93%的抗体反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1131223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","159646","BK4588","SNY","BK4585"],"gpt_icon":0},{"id":"2439699084","title":"美国FDA推迟审批再生元(REGN.US)/赛诺菲(SNY.US)Dupixent用于治疗COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2439699084","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439699084?lang=zh_cn&edition=full","pubTime":"2024-05-31 21:49","pubTimestamp":1717163348,"startTime":"0","endTime":"0","summary":"再生元制药公司(REGN.US)和赛诺菲(SNY.US)周五宣布，美国FDA推迟对其重磅药物Dupixent (dupilumab)用于治疗慢性阻塞性肺疾病(COPD)的决定。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/source/image/46130.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/46130.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0889565916.HKD","LU1917777945.USD","LU1974910355.USD","LU0320765992.SGD","LU0114720955.EUR","BK4585","LU0058720904.USD","SNY","LU2362541513.USD","LU2362541273.HKD","LU0109394709.USD","LU2362540622.SGD","BK4007","LU0053666078.USD","BK4588","LU0882574055.USD","LU0289739699.SGD","LU2106854487.HKD","REGN","BK4139","LU2023250504.SGD"],"gpt_icon":0},{"id":"2439193034","title":"欧洲药品监管机构建议批准赛诺菲(SNY.US) Dupixent用于治疗COPD患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2439193034","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439193034?lang=zh_cn&edition=full","pubTime":"2024-05-31 15:00","pubTimestamp":1717138800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲Dupixent 即将在欧洲获得批准，用于治疗慢性肺病患者，这为这种重磅药物开辟了另一条增长途径。欧洲药品管理局人用药品委员会采纳了一项积极意见，建议在欧盟批准Dupixent治疗慢性阻塞性肺疾病成人患者。两项3期试验表明，Dupixent 可显著减少COPD的急性加重并改善肺功能。预计欧盟委员会将在未来几个月内宣布对Dupixent申请的最终决定。如果获得批准，Dupixent 将成为欧盟首个针对 COPD 的靶向治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","SNY","BK4585","BK4007"],"gpt_icon":0},{"id":"2438389698","title":"赛诺菲(SNY.US)Sarclisa获FDA优先审查 用于治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2438389698","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438389698?lang=zh_cn&edition=full","pubTime":"2024-05-27 20:16","pubTimestamp":1716812166,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲(SNY.US)宣布，其Sarclisa的补充生物制品许可申请 (sBLA)已获得美国FDA优先审查，用于联合硼替佐米、来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤患者。多发性骨髓瘤是一种恶性浆细胞病。赛诺菲表示，FDA决定的目标行动日期为2024年9月27日。该公司补充说，欧盟也在审查一份监管意见书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","SNY","BK4585","BK4007"],"gpt_icon":0},{"id":"2437469066","title":"赛诺菲(SNY.US)携手OpenAI和Formation Bio 促进人工智能驱动药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2437469066","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437469066?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:30","pubTimestamp":1716273049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国制药商赛诺菲安万特(SNY.US)周二宣布，将与人工智能公司OpenAI和Formation Bio合作，使用人工智能推动其药物开发项目。赛诺菲在一份声明中说，与OpenAI的合作将使其能够获得专有数据，为其生物制药模型开发人工智能模型，而Formation Bio将提供额外的工程资源。各大制药商正利用人工智能快速找到临床试验病人，或减少药物测试所需人数，从而加快药物开发，并可能由此节省数百万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","161631","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"2435684715","title":"真有“天上掉馅饼”，诺瓦瓦克斯医药将成为赛诺菲的救星还是花瓶？","url":"https://stock-news.laohu8.com/highlight/detail?id=2435684715","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435684715?lang=zh_cn&edition=full","pubTime":"2024-05-15 17:18","pubTimestamp":1715764725,"startTime":"0","endTime":"0","summary":"当流血经营遇上“天上掉馅饼”根据协议，此次合作赛诺菲首先将向Novavax先支付5亿美元预付款，同时对Novavax进行7000万美元股权投资，占股4.9%。以去年Q1财报为例，Novavax在2023年Q1季度净亏损2.94亿美元。另外，截至2023Q1季度末，Novavax持有现金、现金等价物和限制性现金总计6.37亿美元，与2022年底的13亿美元相比，锐减超过一半。然而赛诺菲并未选择Novavax自有流感新冠联合疫苗。","market":"us","thumbnail":"https://static.tigerbbs.com/bfc4bfef3c2482d46a9efbfa3f98fd4f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bfc4bfef3c2482d46a9efbfa3f98fd4f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVAX","BK4139","BK4585","BK4568","BK4588","BK4007","SNY","BK4547"],"gpt_icon":1},{"id":"2435326368","title":"赛诺菲(SNY.US)将向法国生产基地投资超10亿欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435326368","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435326368?lang=zh_cn&edition=full","pubTime":"2024-05-13 19:14","pubTimestamp":1715598876,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医疗保健公司赛诺菲周一在一份声明中表示，将投资超10亿欧元在法国的三个生产基地Vitry、Le Trait和Lyon Gerland新增生物产能。这些投资是该公司自疫情以来启动的主要项目的补充，旨在增加法国新药和疫苗产能，使其投资总额超过35亿欧元。赛诺菲表示，其全球60%以上的生产在欧盟进行，只有5%的活性成分来自亚洲。该声明是在“选择法国”活动之前发布的，“选择法国”活动是一个旨在为法国吸引海外投资的年度峰会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","SNY","BK4585","BK4007"],"gpt_icon":0},{"id":"2435498603","title":"赛诺菲(SNY)在法国投资10亿欧元用于药物生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2435498603","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435498603?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:25","pubTimestamp":1715588733,"startTime":"0","endTime":"0","summary":"金吾财讯 | 5月13日，赛诺菲(SNY)宣布投资超过10亿欧元，在其位于法国的生产基地建立新的生物生产能力，这项新投资将创造500多个工作岗位。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/MjQ3ZTRjZTI0NDc3MWIxNzE1M2JmYTNmMTgxNzE4MTQwNjE1MDEzMzE4OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MjQ3ZTRjZTI0NDc3MWIxNzE1M2JmYTNmMTgxNzE4MTQwNjE1MDEzMzE4OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"275755","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","SNY","EUO","FXE","EURmain","MEURmain","BK4588"],"gpt_icon":0},{"id":"2434818227","title":"隔夜美股全复盘(5.11)| 极氪刷新了新能源车企史上最快上市纪录，IPO首日收涨超33%，市值一度升至71.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434818227","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434818227?lang=zh_cn&edition=full","pubTime":"2024-05-11 07:10","pubTimestamp":1715382601,"startTime":"0","endTime":"0","summary":"极氪刷新了新能源车企史上最快上市纪录，IPO首日收涨超33%，市值一度升至71.5亿美元","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/729045","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU1691799644.USD","LU2249611893.SGD","GB00B4QBRK32.GBP","BK4538","BP","GB00BDT5M118.USD","BK4532","LU0353189680.USD","LU0310799852.SGD","LU2357305700.SGD","LU0494093205.USD","LU0079474960.USD","BK4533","LU2491049909.HKD","IE00B3S45H60.SGD","LU0211327993.USD","BK4535","LU1280957306.USD","03145","AAPL","LU1551013342.USD","GB00B4LPDJ14.GBP","LU0889565833.HKD","IE00BJJMRX11.SGD","LU0878005551.USD","LU1571399168.USD","BK4534","IE00BBT3K403.USD","LU0061474960.USD","LU0572940350.SGD","LU2491050154.USD","SNY","GOOG","AMZN","TSM","ZK","IE00BJTD4N35.SGD","MRNA","LU1211504680.USD","LU1914381329.SGD","IE00B1XK9C88.USD","LU0384037296.USD","LU2491050071.SGD","NVAX","LU0264606111.USD","LU1804176565.USD","MSFT","NVDA","IE00BKDWB100.SGD","LU1551013425.SGD"],"gpt_icon":0},{"id":"2434503398","title":"美股异动 | 与赛诺菲(SNY.US)达成合作协议 诺瓦瓦克斯医药(NVAX.US)涨超126%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434503398","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434503398?lang=zh_cn&edition=full","pubTime":"2024-05-10 22:30","pubTimestamp":1715351437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，诺瓦瓦克斯医药(NVAX.US)股价走高，截至发稿，该股涨超126%，报10.16美元。该公司与法国制药巨头赛诺菲安万特(SNY.US)达成了一项价值数十亿美元的合作协议。根据协议，双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗，并共同开发针对冠状病毒和流感的组合疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","SNY","NVAX","BK4585","BK4007","BK4139","BK4588"],"gpt_icon":0},{"id":"2434853117","title":"诺瓦瓦克斯医药(NVAX)盘前暴涨超105% 与赛诺菲安万特(SNY)达成价值数十亿美元的合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2434853117","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434853117?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:28","pubTimestamp":1715344112,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺瓦瓦克斯医药(NVAX)盘前暴涨，涨幅最高达200%，暂涨105.15%，报9.17美元。消息面上，公司宣布与法国制药巨头赛诺菲达成一项价值数十亿美元的合作协议。根据协议，双方将从明年开始联合商业化诺瓦瓦克斯医药的新冠疫苗，并共同开发针对冠状病毒和流感的组合疫苗。诺瓦瓦克斯首席执行官John Jacobs表示，这项许可协议将有助于公司解除此前发布的“持续经营”警告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102029148af10bcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102029148af10bcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","NVAX","BK4585","BK4007","BK4139","SNY","BK4588"],"gpt_icon":0},{"id":"2434185871","title":"盘前一度暴涨逾210%！诺瓦瓦克斯医药(NVAX.US)Q1业绩喜忧参半 宣布与赛诺菲(SNY.US)达成12亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2434185871","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434185871?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:07","pubTimestamp":1715342859,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺瓦瓦克斯医药周五公布了喜忧参半的第一季度业绩，与此同时，该公司与法国制药巨头赛诺菲达成了一项价值高达12亿美元的合作协议，并解除了此前发布的“持续经营”警告。根据协议条款，诺瓦瓦克斯医药将在今年剩余时间内主导其新冠疫苗的商业化，并计划于2025年将大部分责任移交给赛诺菲。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4588","BK4007","NVAX","SNY","BK4568","BK4585"],"gpt_icon":0},{"id":"2434188644","title":"诺瓦瓦克斯医药与赛诺菲就新冠疫苗达成数十亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2434188644","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434188644?lang=zh_cn&edition=full","pubTime":"2024-05-10 15:23","pubTimestamp":1715325808,"startTime":"0","endTime":"0","summary":"5月10日，$诺瓦瓦克斯医药$周五宣布，与法国制药巨头$赛诺菲$达成了一项价值数十亿美元的合作协议。此外，诺瓦瓦克斯医药还将从赛诺菲销售的新冠疫苗以及针对冠状病毒和流感的组合疫苗中获得特许权使用费。根据协议条款，诺瓦瓦克斯医药将在今年剩余时间内主导其新冠疫苗的商业化，并计划于2025年将大部分责任移交给赛诺菲。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119740.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVAX","SNY"],"gpt_icon":1},{"id":"2430479922","title":"赛诺菲业绩超预期，Dupixent今年销售额有望达130亿欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430479922","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430479922?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:33","pubTimestamp":1714037620,"startTime":"0","endTime":"0","summary":"财报数据还显示，赛诺菲Altuviiio第一季度的销售额达到1.22亿欧元，而分析师的普遍预期约为1.04亿欧元。赛诺菲重磅的哮喘治疗药物Dupixent的销售额与分析师预期相符，实现同比增长24.9%至28.35 亿欧元。哈德逊在与分析师们的业绩电话会议上表示，今年哮喘治疗药物Dupixent为赛诺菲带来的营收规模有望达到130亿欧元，全球约有85万名患者在服用该药。赛诺菲此后制定了雄心勃勃的扩张计划，以加强其多类型新药物的研发进程，其股价此后开始回升。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"db281c116d914585a115ec9827470da2","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109966.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4588","BK4585","SNY"],"gpt_icon":1},{"id":"2429617118","title":"赛诺菲(SNY.US)潜在“first-in-class”小分子疗法达3期主要终点 预计年底递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429617118","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429617118?lang=zh_cn&edition=full","pubTime":"2024-04-24 10:27","pubTimestamp":1713925624,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月24日，赛诺菲宣布其潜在“first-in-class”可逆布鲁顿氏酪氨酸激酶抑制剂rilzabrutinib达成LUNA 3临床3期试验的主要终点。赛诺菲预计在今年年底前向美国FDA和欧盟提交监管申请。据了解，赛诺菲致力于炎症与免疫学领域疗法的开发。今年2月，赛诺菲公布rilzabrutinib用于治疗中重度CSU患者的2期临床研究RILECSU的积极结果。数据表明rilzabrutinib显著改善了CSU成人患者的瘙痒、荨麻疹和风疹症状，这些症状无法通过H1抗组胺药得到充分控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","SNY","BK4585","BK4007"],"gpt_icon":0},{"id":"2418384693","title":"赛诺菲(SNY.US)公布2b期临床试验支持amlitelimab治疗特应性皮炎潜力结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2418384693","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2418384693?lang=zh_cn&edition=full","pubTime":"2024-03-11 16:09","pubTimestamp":1710144561,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国制药巨头赛诺菲公布了治疗多种炎症的药物amlitelimab 2b期研究STREAM-AD第二部分的积极结果。该结果显示，中度至重度特应性皮炎的成年人患者的体征和症状持续改善28周，这些患者先前对amlitelimab有反应并继续治疗。在停用amlitelimab的参与者中也观察到高应答率。安全性与研究第一部分一致，amlitelimab耐受性良好，未发现新的安全性问题。在所有剂量组中，持续amlitelimab治疗的患者在28周内保持较高的EASI-75和/或IGA 0/1、IGA 0/1和EASI-75应答率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1084434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","SNY","03347","BK1141","BK4007","BK4585","BK1583","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0114},{"period":"3month","weight":0.0396},{"period":"6month","weight":-0.0202},{"period":"1year","weight":-0.08},{"period":"ytd","weight":-0.0028}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.022852},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.021195},{"month":3,"riseRate":0.818182,"avgChangeRate":0.033135},{"month":4,"riseRate":0.681818,"avgChangeRate":0.026182},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.000457},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.014468},{"month":7,"riseRate":0.5,"avgChangeRate":0.016604},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.015597},{"month":9,"riseRate":0.545455,"avgChangeRate":0.009477},{"month":10,"riseRate":0.545455,"avgChangeRate":0.000171},{"month":11,"riseRate":0.636364,"avgChangeRate":0.001886},{"month":12,"riseRate":0.727273,"avgChangeRate":0.03338}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}